Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Nuvail** (poly-ureaurethane 16% nail solution) is an FDA-approved prescription topical product developed by Innocutis for managing signs and symptoms of **nail dystrophy**, such as nail splitting, fragility, and brittleness in intact or damaged nails. It functions mechanically by forming a breathable, waterproof polymer film that adheres strongly to the nail surface, blocking water absorption to prevent the wet-dry cycle that causes damage, while allowing oxygen transfer and protecting against abrasion and friction. Applied daily before bedtime to clean nails, it supports nail plate strengthening without treating underlying infections like onychomycosis, though clinical studies showed improvements in nail parameters and fungal culture negativity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nuvail.